Modeling Alzheimer's disease with non-transgenic rat models

Alzheimer's Research and Therapy

Volumn 5, Issue 3, 2013, Pages

  Lecanu, Laurent ^a   Papadopoulos, Vassilios ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; BUTHIONINE SULFOXIMINE; CAPROSPINOL; CELL THERAPY AGENT; DIPHTHERIA TOXIN; ETHYLCHOLINE MUSTARD AZIRIDINIUM; FATTY ACID DERIVATIVE; FERROUS SULFATE; GAMMA SECRETASE INHIBITOR; IBOTENIC ACID; KAINIC ACID; MYELIN BASIC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; OKADAIC ACID; PARKIN; PLANT EXTRACT; POLYPHENOL DERIVATIVE; SAPORIN; STEROID; STREPTOZOCIN; SYNAPSIN I; TAU PROTEIN; THY 1 ANTIGEN; UNCLASSIFIED DRUG;

AGING; ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL RESEARCH; DEMENTIA; DRUG DESIGN; DRUG EFFICACY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; MAZE TEST; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; REVIEW; RISK FACTOR; TRANSGENIC ANIMAL; WATER MAZE TEST;

EID: 84875920043     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt171     Document Type: Review

References (91)

1. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. Chatellier G, Lacomblez L, BMJ 1990 300 495 499 10.1136/bmj.300.6723.495 2107926
2. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H, BMJ 2005 331 321 327 10.1136/bmj.331.7512. 321 16081444
3. Memantine for dementia. Areosa SA, Sherriff F, McShane R, Cochrane Database Syst Rev 2005 D003154 10.1002/14651858.CD003154.pub3 15846650
4. Needs for animal models of human diseases of the nervous system. Vogel FS, Am J Pathol 1980 101 201 S211 7006405
5. Criteria for development of animal models of diseases of the nervous system. Hadlow WJ, Am J Pathol 1980 101 213 S219 7457572
6. Learning deficit in immature rabbits with aluminum-induced neurofibrillary changes. Rabe A, Lee MH, Shek J, Wisniewski HM, Exp Neurol 1982 76 441 446 10.1016/0014-4886(82)90220-5 6896495
7. Enhanced behavioral response to nicotine in an animal model of Alzheimer's disease. Ksir C, Benson DM, Psychopharmacology (Berl) 1983 81 272 273 10.1007/BF00427277 6417718
8. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Borchelt DR, Ratovitski T, van LJ, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS, Neuron 1997 19 939 945 10.1016/S0896-6273(00)80974-5 9354339
9. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E, Science 2001 293 1487 1491 10.1126/science.1058189 11520987
10. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM, Neuron 2003 39 409 421 10.1016/S0896-6273(03)00434-3 12895417
11. Alzheimer's disease: molecular genetics and transgenic animal models. Lannfelt L, Folkesson R, Mohammed AH, Winblad B, Hellgren D, Duff K, Hardy J, Behav Brain Res 1993 57 207 213 10.1016/0166-4328(93)90137-F 8117426
12. Neurogenesis and Alzheimer's disease: at the crossroads. Lazarov O, Marr RA, Exp Neurol 2010 223 267 281 10.1016/j.expneurol.2009.08.009 19699201
13. The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease. Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC, Tan EK, Cell Adh Migr 2011 5 280 292 10.4161/cam.5.4.16986 21785276
14. The role of APP and APLP for synaptic transmission, plasticity, and network function: lessons from genetic mouse models. Korte M, Herrmann U, Zhang X, Draguhn A, Exp Brain Res 2012 217 435 440 10.1007/s00221-011-2894-6 22006270
15. FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease. Platt B, Welch A, Riedel G, Biochem Soc Trans 2011 39 874 880 10.1042/BST0390874 21787316
16. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J, Prog Neurobiol 2011 95 547 556 10.1016/j.pneurobio.2011.05.004 21601614
17. APP transgenic mice: their use and limitations. Balducci C, Forloni G, Neuromol Med 2011 13 117 137 10.1007/s12017-010-8141-7 21152995
18. Recent rodent models for Alzheimer's disease: clinical implications and basic research. Braidy N, Munoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, Sachdev P, Guillemin GJ, J Neural Transm 2012 119 173 195 10.1007/s00702-011-0731-5 22086139
19. An attempt to produce cholinergic hypofunction in rat brain using choline mustard aziridinium ion: neurochemical and histological parameters. Colhoun EH, Myles LA, Rylett RJ, Can J Neurol Sci 1986 13 517 520 3791065
20. Ethylcholine mustard aziridinium ion lesions of the rat cortex result in retrograde degeneration of basal forebrain cholinergic neurons: implications for animal models of neurodegenerative disease. Stephens PH, Tagari P, Cuello AC, Neurochem Res 1987 12 613 618 10.1007/BF00971009 3614511
21. Are the neurochemical and behavioral changes induced by lesions of the nucleus basalis in the rat a model of Alzheimer's disease? Pepeu G, Casamenti F, Pedata F, Cosi C, Pepeu IM, Prog Neuropsychopharmacol Biol Psychiatry 1986 10 541 551 10.1016/0278-5846(86)90024-2 2879319
22. Effects of intracerebroventricular injection of AF64A on learning behaviors in rats. Nakahara N, Iga Y, Mizobe F, Kawanishi G, Jpn J Pharmacol 1988 48 121 130 10.1254/jjp.48.121 3199599
23. Monosodium glutamate effects. Olney JW, Adamo NJ, Ratner A, Science 1971 172 294 10.1126/science.172.3980.294 5102256
24. Cholinergic ventral forebrain grafts into the neocortex improve passive avoidance memory in a rat model of Alzheimer disease. Fine A, Dunnett SB, Bjorklund A, Iversen SD, Proc Natl Acad Sci USA 1985 82 5227 5230 10.1073/pnas.82.15.5227 3860857
25. Loss of cholinergic neurons in the rat neocortex produces deficits in passive avoidance learning. Friedman E, Lerer B, Kuster J, Pharmacol Biochem Behav 1983 19 309 312 10.1016/0091-3057(83)90057-6 6634880
26. An attempt to cause the selective loss of the cholinergic neurons in the basal forebrain of the rat: a new animal model of Alzheimer's disease. Kudo Y, Shiosaka S, Matsuda M, Tohyama M, Neurosci Lett 1989 102 125 130 10.1016/0304-3940(89)90066-9 2682384
27. Transplantation of human cortex with Alzheimer's disease into rat occipital cortex; a model for the study of Alzheimer disease. van den Bosch de Aguilar, Langhendries-Weverberg C, Goemaere-Vanneste J, Flament-Durand J, Brion JP, Couck AM, Experientia 1984 40 402 403 10.1007/BF01952575 6714374
28. Nicotine and Alzheimer's disease. Jones G, Levy R, Sahakian B, Br J Psychiatry 1990 156 280 281 2317633
29. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognitionenhancing and anxiolytic activities: II. In vivo characterization. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT, et al. J Pharmacol Exp Ther 1994 270 319 328 7913497
30. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Frautschy SA, Cole GM, Baird A, Am J Pathol 1992 140 1389 1399 1376558
31. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Ingram DK, Spangler EL, Iijima S, Ikari H, Kuo H, Greig NH, London ED, Life Sci 1994 55 2037 2049 10.1016/0024-3205(94)00384-X 7997063
32. Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, Rossner S, Bigl V, Prog Brain Res 1996 109 253 264 9009714
33. Hippocampal injections of amyloid betapeptide 1-40 impair subsequent one-trial/day reward learning. Malin DH, Crothers MK, Lake JR, Goyarzu P, Plotner RE, Garcia SA, Spell SH, Tomsic BJ, Giordano T, Kowall NW, Neurobiol Learn Mem 2001 76 125 137 10.1006/nlme.2000.3991 11502145
34. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. Stephan A, Laroche S, Davis S, J Neurosci 2001 21 5703 5714 11466442
35. Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Lecanu L, Greeson J, Papadopoulos V, Pharmacology 2006 76 19 33 10.1159/000088929 16224201
36. Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)- amyloid peptide. Nakamura S, Murayama N, Noshita T, Annoura H, Ohno T, Brain Res 2001 912 128 136 10.1016/S0006-8993(01)02704-4 11532428
37. Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. Arif M, Chikuma T, Ahmed MM, Nakazato M, Smith MA, Kato T, Neuroscience 2009 164 1199 1209 10.1016/j.neuroscience.2009.08.063 19733635
38. Alzheimer's disease could be type 3 diabetes Pilcher H, Lancet Neurol 2006 5 388 389 16639835
39. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. de la Monte SM, Tong M, J Alzheimers Dis 2009 17 817 825 19542621
40. Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. Grunblatt E, Hoyer S, Riederer P, J Neural Transm 2004 111 367 386 10.1007/s00702-003-0030-x 14991460
41. Genistein ameliorates learning and memory deficits in amyloid beta(1-40) rat model of Alzheimer's disease. Bagheri M, Joghataei MT, Mohseni S, Roghani M, Neurobiol Learn Mem 2011 95 270 276 10.1016/j.nlm.2010.12.001 21144907
42. Neuroprotective effect of the aminoestrogen prolame against impairment of learning and memory skills in rats injected with amyloid-beta(-)(2)(5)(-)(3)(5) into the hippocampus. Limon D, Diaz A, Hernandez M, Fernandez G, Torres-Martinez AC, Perez-Severiano F, Rendon-Huerta EP, Montano LF, Guevara J, Eur J Pharmacol 2012 685 74 80 10.1016/j.ejphar.2012.04.020 22542664
43. Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's disease. Lecanu L, Rammouz G, McCourty A, Sidahmed EK, Greeson J, Papadopoulos V, Neuroscience 2010 165 427 435 10.1016/j. neuroscience.2009.10.033 19850110
44. Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimer's disease rat model. Di SA, Sozio P, Cerasa LS, Iannitelli A, Cataldi A, Zara S, Giorgioni G, Nasuti C, Int J Immunopathol Pharmacol 2010 23 589 599 20646354
45. A comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an Abeta plus ibotenic acid-infused rat model of Alzheimer's disease. Ahmed T, Gilani AH, Brain Res 2011 1400 1 18 21640982
46. Aqueous extract of lavender (Lavandula angustifolia) improves the spatial performance of a rat model of Alzheimer's disease. Kashani MS, Tavirani MR, Talaei SA, Salami M, Neurosci Bull 2011 27 99 106 10.1007/s12264-011-1149-7 21441971
47. Scavenging effect of Naoerkang on amyloid beta-peptide deposition in the hippocampus in a rat model of Alzheimer's disease. Li X, Yuan HF, Quan QK, Wang JJ, Wang NN, Li M, Chin J Integr Med 2011 17 847 853 10.1007/s11655-011-0896-7 22057414
48. Elevation of BACE in an Abeta rat model of Alzheimer's disease: exacerbation by chronic stress and prevention by nicotine. Alkadhi KA, Alzoubi KH, Srivareerat M, Tran TT, Int J Neuropsychopharmacol 2012 15 223 233 10.1017/S1461145711000162 21356140
49. Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease. Han M, Liu Y, Tan Q, Zhang B, Wang W, Liu J, Zhang XJ, Wang YY, Zhang JM, Eur J Pharmacol 2011 657 104 110 10.1016/j.ejphar.2011.01.065 21316359
50. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C, Neurosci Lett 2011 487 70 72 10.1016/j.neulet.2010.09.076 20933058
51. Paeonol increases levels of cortical cytochrome oxidase and vascular actin and improves behavior in a rat model of Alzheimer's disease. Zhou J, Zhou L, Hou D, Tang J, Sun J, Bondy SC, Brain Res 2011 1388 141 147 21377451
52. Effects of 8-residue beta sheet breaker peptides on aged Abeta40-induced memory impairment and Abeta40 expression in rat brain and serum following intraamygdaloid injection. Hatip FF, Hatip-Al-Khatib I, Matsunaga Y, Suenaga M, Sen N, Curr Alzheimer Res 2010 7 602 614 10.2174/156720510793499048 20977411
53. Brain and serum levels of nerve growth factor in a rat model of Alzheimer's disease. Gelfo F, Tirassa P, De BP, Caltagirone C, Petrosini L, Angelucci F, J Alzheimers Dis 2011 25 213 217 21368378
54. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P, J Neurochem 2006 96 1005 1015 10.1111/j.1471-4159.2005.03637.x 16412093
55. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. Salkovic-Petrisic M, Osmanovic-Barilar J, Bruckner MK, Hoyer S, Arendt T, Riederer P, J Neural Transm 2011 118 765 772 10.1007/s00702-011-0651-4 21533606
56. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Lim YW, Yoon SY, Choi JE, Kim SM, Lee HS, Choe H, Lee SC, Kim DH, Biochem Biophys Res Commun 2010 395 207 212 10.1016/j.bbrc.2010.03.163 20362550
57. Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer's disease. Aly HF, Metwally FM, Ahmed HH, Acta Biochim Pol 2011 58 513 520 22146133
58. Cbl-b regulates the CD28 dependence of T-cell activation. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H, Nature 2000 403 216 220 10.1038/35003235 10646609
59. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Yokoi N, Komeda K, Wang HY, Yano H, Kitada K, Saitoh Y, Seino Y, Yasuda K, Serikawa T, Seino S, Nat Genet 2002 31 391 394 12118252
60. Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia. Zito G, Polimanti R, Panetta V, Ventriglia M, Salustri C, Siotto MC, Moff a F, Altamura C, Vernieri F, Lupoi D, Cassetta E, Rossini PM, Squitti R, Rejuvenation Res 2013 16 51 56 10.1089/rej.2012.1383 23216585
61. Oxidative stress: free radical production in neural degeneration. Gotz ME, Kunig G, Riederer P, Youdim MB, Pharmacol Ther 1994 63 37 122 10.1016/0163-7258(94)90055-8 7972344
62. Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Gutteridge JM, Ann N Y Acad Sci 1994 738 201 213 7832429
63. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. Martins RN, Harper CG, Stokes GB, Masters CL, J Neurochem 1986 46 1042 1045 10.1111/j.1471-4159.1986.tb00615.x 3950618
64. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: new approach to therapy. Sochocka M, Koutsouraki ES, Gasiorowski K, Leszek J, CNS Neurol Disord Drug Targets 2013 23469836
65. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Yan MH, Wang X, Zhu X, Free Radic Biol Med 2012 pii 0891 5849(12)01823-0 10.1016/j.freeradbiomed.2012.11.014 23200807
66. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Butterfield DA, Swomley AM, Sultana R, Antioxid Redox Signal 2013 10.1089/ars.2012.5027 23249141
67. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Fagan AM, Perrin RJ, Biomark Med 2012 6 455 476 10.2217/bmm.12.42 22917147
68. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P, Biochem J 1994 301 871 877 7519852
69. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van d, Martin JJ, Cras P, J Neurochem 1993 61 1828 1834 10.1111/j.1471-4159.1993.tb09823.x 8228996
70. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, Neurol Sci 2001 22 77 78 10.1007/s100720170055 11487210
71. Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties. Papadopoulos V, Lecanu L, J Neuroendocrinol 2012 24 93 101 10.1111/j.1365-2826.2011.02167.x 21623958
72. Caprospinol: moving from a neuroactive steroid to a neurotropic drug. Lecanu L, Tillement L, Rammouz G, Tillement JP, Greeson J, Papadopoulos V, Expert Opin Investig Drugs 2009 18 265 276 10.1517/13543780902762827 19243278
73. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. Amijee H, Scopes DI, J Alzheimers Dis 2009 17 33 47 19221409
74. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Cai Z, Zhao B, Ratka A, Neuromol Med 2011 13 223 250 10.1007/s12017-011-8155-9 21901428
75. Reversal of propoxur-induced impairment of step-down passive avoidance, transfer latency and oxidative stress by piracetam and ascorbic acid in rats. Gupta S, Garg GR, Bharal N, Mediratta PK, Banerjee BD, Sharma KK, Environ Toxicol Pharmacol 2009 28 403 408 10.1016/j.etap.2009.06.007 21784034
76. Samaritan Alzheimer's Rat Model™ http://www.taconic.com/user- assets/Documents/Surgery-Samaritan.pdf
77. Attenuated hippocampus-dependent learning and memory decline in transgenic TgAPPswe Fischer-344 rats. Ruiz-Opazo N, Kosik KS, Lopez LV, Bagamasbad P, Ponce LR, Herrera VL, Mol Med 2004 10 36 44 15502881
78. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC, J Alzheimers Dis 2010 20 113 126 20164597
79. Rat transgenic models with a phenotype of intracellular Abeta accumulation in hippocampus and cortex. Echeverria V, Ducatenzeiler A, Alhonen L, Janne J, Grant SM, Wandosell F, Muro A, Baralle F, Li H, Duff K, Szyf M, Cuello A, J Alzheimers Dis 2004 6 209 219 15201476
80. Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer's disease. Kloskowska E, Pham TM, Nilsson T, Zhu S, Oberg J, Codita A, Pedersen LA, Pedersen JT, Malkiewicz K, Winblad B, Folkesson R, Benedikz E, J Cell Mol Med 2010 14 1816 1823 19538474
81. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. Flood DG, Lin YG, Lang DM, Trusko SP, Hirsch JD, Savage MJ, Scott RW, Howland DS, Neurobiol Aging 2009 30 1078 1090 10.1016/j.neurobiolaging.2007. 10.006 18053619
82. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K, Neurobiol Dis 2008 31 46 57 10.1016/j.nbd.2008.03.005 18504134
83. Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically. Agca C, Fritz JJ, Walker LC, Levey AI, Chan AW, Lah JJ, Agca Y, BMC Neurosci 2008 9 28 10.1186/1471-2202-9-28 18302776
84. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M, Brain Res 2007 1130 206 213 17169350
85. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M, Eur J Neurosci 2008 28 239 246 18702695
86. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M, FEBS Lett 2006 580 3582 3588 10.1016/j.febslet.2006.05.029 16753151
87. Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides. Lewis PA, Piper S, Baker M, Onstead L, Murphy MP, Hardy J, Wang R, McGowan E, Golde TE, Biochim Biophys Acta 2001 1537 58 62 10.1016/S0925-4439(01)00054-0 11476963
88. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE, Mol Neurodegener 2007 2 11 10.1186/1750-1326-2-11 17559680
89. A stopcodon mutation in the BRI gene associated with familial British dementia. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J, Nature 1999 399 776 781 10.1038/21637 10391242
90. Parkin promotes intracellular Abeta1-42 clearance. Burns MP, Zhang L, Rebeck GW, Querfurth HW, Moussa CE, Hum Mol Genet 2009 18 3206 3216 10.1093/hmg/ddp258 19483198
91. Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. Rebeck GW, Hoe HS, Moussa CE, J Biol Chem 2010 285 7440 7446 10.1074/jbc.M109.083915 20071340